Allergen immunotherapy

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

Peanut butter
#Allergen immunotherapy #Allergy #Clinical trial

Immunotherapy could treat nut allergies, results show 

A new immunotherapy could treat patients with nut allergies, preliminary results show.  VLP Peanut, an immunotherapy developed by biotechnology company Allergy Therapeutics, reached its primary endpoint in the Phase I/IIa PROTECT trial, with results showing the immunotherapy was safe and well-tolerated. The treatment was evaluated in 48 patients, with a… Read More

#News

Cat in a box
#Allergen immunotherapy #Allergy #Monoclonal antibodies

Combination treatment could be more effective for cat allergy

New research has shown that standard cat allergy treatment can be enhanced to make it more effective and faster acting, and the benefits last for a year after treatment ends. These results show for the first time that adding a cytokine inhibitor to allergy shots could reduce allergic rhinitis symptoms… Read More

#News #Trending News